- New

VELMETIA is a combination medication used to improve glycemic control in adults with type 2 diabetes.
Description:
1. Formulation
(a) Each tablet contains:
o Sitagliptin phosphate: A dipeptidyl peptidase 4 (DPP-4) inhibitor.
o Metformin hydrochloride: A biguanide antihyperglycemic agent.
(b) Available strengths: 50 mg sitagliptin + 500 mg metformin.
2. Indications
(a) VELMETIA is prescribed as an adjunct to diet and exercise:
o When patients are inadequately controlled on maximal tolerated dose of metformin alone.
o For patients already treated with the combination of sitagliptin and metformin.
o It helps improve blood sugar levels.
3. Contraindications
(a) Avoid VELMETIA if you have:
o Hypersensitivity to sitagliptin or metformin.
o Acute or chronic metabolic acidosis (including diabetic ketoacidosis).
o Severe renal impairment (eGFR <30 mL/min/1.73 m?).
o Pregnancy and lactation.